ArticleAmerican journal of translational research2025
Effects of stellate ganglion block on inflammation and autophagy of spinal cord neurons in rats with neuropathic pain after spinal cord injury.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy and safety of stellate ganglion block for postherpetic neuralgia: a systematic review and meta-analysis protocol.BMJ open · 2026Article
- The analgesic effect of electroacupuncture in alleviating paclitaxel-induced peripheral neuropathic pain and its possible mechanism relates to TLR4/P2X7-NLRP3 signaling pathway.Purinergic signalling · 2026Article
- Anatomy, Imaging, and Clinical Significance of the Cervicothoracic (Stellate) Ganglion.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the therapeutic effects of stellate ganglion block (SGB) on spinal cord injury (SCI)-induced neuropathic pain in rats, and to explore its potential mechanisms in alleviating neuropathic pain, thereby providing a theoretical foundation for clinical treatment.
methodsA rat model of SCI was established, and animals were randomly assigned to one of three groups: the sham surgery group (Sham), the SCI group (SCI), or the SCI group treated with SGB (SCI + SGB). Motor function was assessed using the Basso Beattie Bresnahan (BBB) locomotor rating scale, while thermal hyperalgesia was evaluated using hot plate test. Enzyme-linked immunosorbent assay (ELISA) was utilized to measure the levels of inflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α), within the spinal cord. Hematoxylin-eosin (HE) staining was performed to observe spinal cord histopathology. Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was used to detect apoptotic cells, and transmission electron microscopy was employed to visualize autophagosomes. Expression of autophagy-related proteins LC3-II/LC3-I and p62 was examined via Western blotting.
resultsCompared with the sham group, rats in the SCI group displayed impaired hind limb motor function, decreased pain thresholds, elevated inflammatory cytokine levels, significant spinal cord pathology, increased apoptosis, altered expression of autophagy-related protein, and disrupted autophagic flux. In contrast, SGB treatment improved motor function, alleviated pain, reduced inflammatory cytokines levels, mitigated spinal cord injury and apoptosis, and enhanced autophagy with improved autophagic flux.
conclusionsStellate ganglion block alleviates neuropathic pain in SCI-induced rats by reducing pro-inflammatory cytokine levels, mitigating spinal cord apoptosis and injury, promoting autophagy, and restoring autophagic flux in the spinal cord.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.